Figure S2. (A) Kaplan-Meier curves of overall survival between patients in the development and validation cohorts (log-rank test, *P* = 0.594); (B) Kaplan-Meier curves of overall survival between patients with and without adjuvant TACE in the developing cohort (log-rank test, *P* < 0.001); and (C) Kaplan-Meier curves of overall survival between patients with and without adjuvant TACE in the validation cohort (log-rank test, *P* < 0.001). Number of patients at risk and censoring were list in the box at the bottom of each plot.

